{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:01:22Z","timestamp":1781334082154,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006482","name":"Clalit Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006482","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.clml.2018.06.026","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T13:03:48Z","timestamp":1529931828000},"page":"e449-e461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre\u2013Post Intervention Multicenter Pilot Study"],"prefix":"10.1016","volume":"18","author":[{"given":"Avi","family":"Leader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Benyamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Gafter-Gvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronya","family":"Calvarysky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Amitai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat","family":"Yarchovsky-Dolberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giora","family":"Sharf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8798-8127","authenticated-orcid":false,"given":"Eric","family":"Tousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opher","family":"Caspi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"De Geest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.06.026_bib1","first-page":"1497","article-title":"A\u00a0minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.clml.2018.06.026_bib2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.026_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood.V112.11.186.186","volume":"112","author":"O'Brien","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.026_bib4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.026_bib5","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.026_bib6","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.026_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/blood.V120.21.163.163","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.026_bib8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.06.026_bib9","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.026_bib10","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.026_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2018.06.026_bib12","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2016.67.4184","article-title":"Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia","volume":"34","author":"Winn","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.026_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.06.026_bib14","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.026_bib15","unstructured":"Abraham I, Lee C, MacDonald K, et\u00a0al. No margin for non-adherence: novel application of Kaplan-Meier methods to model the efficacy of adherence to imatinib treatment by patients with chronic myeloid leukemia (the ADAGIO study). Presented at the European Society for Patient Adherence, Compliance and Persistence, Ghent, Belgium, October 25-27, 2012 (abstract 4)."},{"key":"10.1016\/j.clml.2018.06.026_bib16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.026_bib17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A\u00a0new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2018.06.026_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-pharmtox-011711-113247","article-title":"Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories","volume":"52","author":"Blaschke","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.clml.2018.06.026_bib19","first-page":"CD000011","article-title":"Interventions for enhancing medication adherence","author":"Nieuwlaat","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2018.06.026_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12160-013-9486-6","article-title":"The behavior change technique taxonomy (V1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions","volume":"46","author":"Michie","year":"2013","journal-title":"Ann Behav Med"},{"key":"10.1016\/j.clml.2018.06.026_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/0193945911434518","article-title":"An ecological perspective on medication adherence","volume":"34","author":"Berben","year":"2012","journal-title":"West J Nurs Res"},{"key":"10.1016\/j.clml.2018.06.026_bib22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.7326\/0003-4819-157-11-201212040-00538","article-title":"Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review","volume":"157","author":"Viswanathan","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2018.06.026_bib23","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"Eliasson","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.06.026_bib24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.026_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.critrevonc.2015.08.025","article-title":"To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients","volume":"97","author":"Hall","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2018.06.026_bib26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","article-title":"Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries","volume":"143","author":"Geissler","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.026_bib27","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s12032-011-9926-8","article-title":"Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients","volume":"29","author":"Moon","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2018.06.026_bib28","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1111\/jan.12978","article-title":"Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study","volume":"72","author":"Kek\u00e4le","year":"2016","journal-title":"J\u00a0Adv Nurs"},{"key":"10.1016\/j.clml.2018.06.026_bib29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2012.082511","article-title":"Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges","volume":"99","author":"Noens","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.06.026_bib30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure in an outpatient setting","volume":"10","author":"Morisky","year":"2008","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"9","key":"10.1016\/j.clml.2018.06.026_bib31","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/j.clml.2018.06.007","article-title":"Identifying Tyrosine Kinase Inhibitor Non-adherence in Chronic Myeloid Leukemia: a sub-analysis of the TAKE-IT pilot study","volume":"18","author":"Leader","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.06.026_bib32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.026_bib33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.leukres.2012.01.021","article-title":"Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia","volume":"36","author":"Gater","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.06.026_bib34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40265-013-0041-3","article-title":"Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis","volume":"73","author":"Demonceau","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.clml.2018.06.026_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/109019818801500401","article-title":"An ecological perspective on health promotion programs","volume":"15","author":"McLeroy","year":"1988","journal-title":"Health Educ Q"},{"key":"10.1016\/j.clml.2018.06.026_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pec.2013.07.012","article-title":"Motivational interviewing in medical care settings: a systematic review and meta-analysis of randomized controlled trials","volume":"93","author":"Lundahl","year":"2013","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.clml.2018.06.026_bib37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.healun.2017.01.007","article-title":"Efficacy of a medication adherence enhancing intervention in transplantation: the MAESTRO-Tx trial","volume":"36","author":"Dobbels","year":"2017","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.clml.2018.06.026_bib38","first-page":"183","article-title":"Stages of change in the modification of problem behaviors","volume":"28","author":"Prochaska","year":"1992","journal-title":"Prog Behav Modif"},{"key":"10.1016\/j.clml.2018.06.026_bib39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/01.qai.0000246034.86135.89","article-title":"Use of electronic monitoring induces a 40-day intervention effect in HIV patients","volume":"43","author":"Deschamps","year":"2006","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.clml.2018.06.026_bib40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.026_bib41","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2016-07-726893","article-title":"Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study","volume":"129","author":"Landier","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.026_bib42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1377\/hlthaff.2009.1087","article-title":"Medication adherence leads to lower health care use and costs despite increased drug spending","volume":"30","author":"Roebuck","year":"2011","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.clml.2018.06.026_bib43","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.1182\/blood.V110.11.5159.5159","article-title":"Compliance with imatinib mesylate associated with lower health resource utilization and costs for patients with CML and GIST","volume":"110","author":"Halpern","year":"2015","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018303872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018303872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:17Z","timestamp":1761870677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018303872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S2152265018303872"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.06.026","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre\u2013Post Intervention Multicenter Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}